Note 1 - Formation and Business of the Company (Details Textual) - USD ($)			1 Months Ended		2 Months Ended	3 Months Ended		6 Months Ended		8 Months Ended	42 Months Ended
	Nov. 06, 2020	Jun. 01, 2016	Apr. 30, 2021	Jul. 31, 2016	Dec. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Nov. 30, 2019	Jul. 31, 2021
Revenue from Contract with Customer, Excluding Assessed Tax, Total						$ 3,789,000	$ 0	$ 4,045,000	$ 0
3D Medicines, Inc [Member]
Proceeds from Collaborators					$ 12,000,000	6,000,000		6,000,000		$ 18,000,000
Proceeds from Milestone Achievement			$ 6,000,000
3D Medicines, Inc [Member] | Subsequent Event [Member]
Collaborative Agreement, Expected Milestone Payments to be Received												$ 3,000,000
3D Medicines, Inc [Member] | Mainland China,Taiwan, Hong Kong and Macau [Member]
Proceeds from Collaborators	$ 12,000,000
Cancer Prevention and Research Institute of Texas [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total				$ 20,000,000.0
Percentage of Cash Required to Raise in Matching Funds		50.00%
Cash Required to Raise in Matching Funds		$ 10,000,000.0
Matching Funds Required to Raise, Project Term (Year)		3 years
Cash Required in Matching Funds, Amount Raised											$ 10,000,000.0
Percentage of Grant Award Proceeds Required to Pay		400.00%
Maximum Percentage of Grant Award Proceeds Required to Pay Thereafter Until Government Exclusivity Maintained		1.00%
Leland Stanford Junior University [Member]
Maximum Milestone Payments Upon Achievement of Clinical and Regulatory Milestones						$ 1,000,000		$ 1,000,000		$ 1,000,000